Cancer Treatment-Induced Bone Loss in Hormone-Sensitive Cancer: The Paradigm of Cancer Survivor Bone Health Management

Abstract

Cancer therapy-induced bone loss (CTIBL), occurring especially in hormone-treated breast and prostate cancer patients, is a noteworthy long-term consequence of cancer treatments. Because of its negative impact on the quality life of cancer survivors, it deserves much attention. We here summarize the pathophysiology of CTIBL in breast and prostate cancer, its clinical presentation, management, and treatment.